½ÃÀ庸°í¼­
»óǰÄÚµå
1372005

¼¼°è °£Áú ¸ð´ÏÅ͸µ ±â±â ½ÃÀå ¿¹Ãø : Á¦Ç° À¯Çü, ±â¼ú, ȯÀÚ À¯Çü, À¯Åë ä³Î, ÃÖÁ¾ »ç¿ëÀÚ, Áö¿ªº° ºÐ¼®(-2030³â)

Epilepsy Monitoring Devices Market Forecasts to 2030 - Global Analysis By Product (Conventional Devices and Wearable Devices), Type, Technology, Patient Type, Distribution Channel, End User and By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Stratistics Market Research Consulting | ÆäÀÌÁö Á¤º¸: ¿µ¹® 200+ Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Stratistics MRC¿¡ µû¸£¸é °£Áú ¸ð´ÏÅ͸µ ±â±â ¼¼°è ½ÃÀåÀº 2023³â¿¡ 5¾ï 5,670¸¸ ´Þ·¯¸¦ Â÷ÁöÇϰí, ¿¹Ãø ±â°£ Áß º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 6.7%¸¦ ³ªÅ¸³¾ Àü¸ÁÀ̸ç, 2030³â¿¡´Â 8¾ï 7,650¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

°£ÁúÀº ¹Ýº¹ÀûÀ¸·Î ¹ß»ýÇÏ´Â ¹ßÀÛÀÌ Æ¯Â¡ÀûÀÎ ½Å°æ ÁúȯÀ̸ç, °£Áú ¸ð´ÏÅ͸µ ±â±â´Â °£ÁúÀÇ »óŸ¦ È®ÀÎ, ÃßÀû ¹× °ü¸®Çϱâ À§ÇØ ÀÇ·á¿¡¼­ »ç¿ëµÇ´Â ±â±â ¹× ±â¼úÀÔ´Ï´Ù. ÀÌ·¯ÇÑ µµ±¸´Â °£ÁúÀÇ Á¶±â ¹ß°ß ¹× °ü¸® ¹× °£Áú ȯÀÚÀÇ QOL Çâ»ó¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÀÌ ÈÞ´ë¿ë ³úÆÄ°è°¡ ÀÖÀ¸¸é ȯÀÚ´Â ÀÏ»ó »ýȰÀ» º¸³»¸é¼­ ¸ð´ÏÅ͸µ ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¾à¹° ÀúÇ×¼º °£Áú ȯÀÚÀÇ ³ú Ȱµ¿À» Æ÷ÂøÇϱâ À§ÇØ ³ú¿¡ Àü±ØÀ» »ðÀÔÇÏ´Â °ÍÀÌ Æ÷ÇԵ˴ϴÙ. ºñħ½ÀÀû ³úÆÄ °Ë»ç·Î ÃæºÐÇÑ ¼¼ºÎ»çÇ×À» ¾òÀ» ¼ö ¾ø´Â °æ¿ì ³úÆÄ °Ë»ç°¡ ¼öÇàµË´Ï´Ù.

¼¼°èº¸°Ç±â±¸(WHO)°¡ 2022³â 2¿ù¿¡ ¹ßÇ¥ÇÑ ÃÖ½ÅÁ¤º¸¿¡ µû¸£¸é °£ÁúȯÀÚ ¼ö´Â ¼¼°è¿¡¼­ ¾à 5,000¸¸ ¸í¿¡ À̸£¸ç ¼¼°èÀûÀ¸·Î °¡Àå ÈçÇÑ ½Å°æÁúȯ Áß Çϳª°¡ µÇ°í ÀÖ½À´Ï´Ù.

°£ÁúÀ¯º´·ü Áõ°¡

°£Áú ȯÀÚ ¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó °£Áú ¸ð´ÏÅ͸µ ±â±âÀÇ Çʿ伺µµ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. Áúº´À» ¼º°øÀûÀ¸·Î °ü¸®Çϱâ À§ÇØ Áõ°¡Çϴ ȯÀÚ Áý´ÜÀº Áø´Ü ¹× ¸ð´ÏÅ͸µ ±â±â¸¦ Ãß°¡ÇؾßÇÕ´Ï´Ù. ¶ÇÇÑ È¯ÀÚ ¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó Ä¡·á ÃÖÀûÈ­°¡ ÇÊ¿äÇÕ´Ï´Ù. ÃÖÀûÀÇ Ä¡·á¹ýÀ» äÅÃÇϰí ÀûÀýÇÑ ¾çÀÇ ÀǾàǰÀ» Á¦°øÇϱâ À§ÇØ, ¸ð´ÏÅ͸µ ±â±â´Â ÀÇ·á Á¾»çÀÚ°¡ °¢ ȯÀÚ¿¡°Ô Ä¡·á ¿ä¹ýÀ» ¸ÂÃãÈ­ÇÏ´Â µ¥ µµ¿òÀ» ÁÖ°í °£Áú ºóµµ »ó½Â°ú ½Î¿ì±â À§ÇØ Á¤ºÎ Á¶Á÷°ú ÀÇ·á ±â°üÀº ÀÚÁÖ °øÁß º¸°Ç Ä·ÆäÀÎÀ» ¹èÆ÷ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ³ë·ÂÀº ¸ð´ÏÅ͸µ ¹× Áø´Ü ¼­ºñ½º¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» Çâ»ó½ÃŰ°í ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÕ´Ï´Ù.

³ôÀº ºñ¿ëÀ¸·Î ¾×¼¼½º Á¦ÇÑ

°£Áú ¸ð´ÏÅ͸µ ±â±â¿¡ ´ëÇÑ ¾×¼¼½º´Â ƯÈ÷ ÃæºÐÇÑ º¸ÇèÀ̳ª Àç¿øÀÌ ¾ø´Â °³Àο¡°Ô´Â °í°¡ÀÇ ºñ¿ëÀ¸·Î ¹æÇعÞÀ» ¼ö ÀÖ½À´Ï´Ù. ±× °á°ú Áø´ÜÀ̳ª Ä¡·á°¡ ºÒÃæºÐÇϰųª Áö¿¬µÉ ¼ö ÀÖ½À´Ï´Ù. ¸ð´ÏÅ͸µ ±â±â¿¡ ¸¹Àº ºñ¿ëÀ» ÁöºÒÇØ¾ß Çϴ ȯÀÚ´Â °æÁ¦Àû ¾î·Á¿òÀ» °ÞÀ» ¼ö ÀÖ½À´Ï´Ù. ±× °á°ú ÇÊ¿äÇÑ Áø´ÜÀ̳ª ÀǷḦ ¹ÞÁö ¸øÇÒ ¼ö ÀÖ½À´Ï´Ù. ¸ð´ÏÅ͸µ ±â±âÀÇ °í°¡ÀÇ ÁöÃâÀº ºó°ï±¹ µî ÀÚ¿øÀÌ ºÎÁ·ÇÑ Áö¿ª¿¡¼­ÀÇ Ã¤¿ëÀ» ¿ÏÀüÈ÷ ±ÝÁöÇÒ °¡´É¼ºÀÌ ÀÖÀ¸¸ç, °£ÁúȯÀÚ¿¡ ´ëÇÑ ¼­ºñ½º°¡ Áö³ªÄ¡°Ô À¯ÁöµÇÁö ¾Ê±â ¶§¹®¿¡ ½ÃÀå ¼ºÀåÀÇ ¹æÇذ¡ µË´Ï´Ù.

À¯·®À» º¯°æÇÏ°í °í¾ÐÀ¸·Î ¸¸µå´Â ´É·Â

½Ç½Ã°£ µ¥ÀÌÅÍ ºÐ¼®, ¸ð´ÏÅ͸µ ä³Î Ãß°¡, ½ÅÈ£ ó¸® Çâ»óÀº ¸ðµÎ µðÁöÅÐ EEG ½Ã½ºÅÛÀÇ Æ¯Â¡ÀÔ´Ï´Ù. °í¹Ðµµ EEG ½Ã½ºÅÛ¿¡¼­´Â ³ú Ȱµ¿À» ±â·ÏÇϱâ À§ÇØ ´õ ¸¹Àº Àü±ØÀÌ »ç¿ëµË´Ï´Ù. ÀÌ·¯ÇÑ ±â±â´Â º¸´Ù Á¤È®ÇÑ Áö¸®Àû µ¥ÀÌÅ͸¦ Á¦°øÇÏ°í °£Áú ¹ßÀÛÀÇ Ãâó¸¦ ÆÄ¾ÇÇÏ°í °£Áú Ȱµ¿À» º¸´Ù Á¤È®ÇÏ°Ô ¼³¸íÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¿þ¾î·¯ºí EEG Çìµå¼Â°ú °°Àº ¸ð´ÏÅ͸µ ±â±âÀÇ ¼ÒÇüÈ­·Î ÀÎÇØ ¸ð´ÏÅ͸µÀÌ ´õ ¹æÇذ¡ µÇÁö ¾Ê°í »ç¿ëÇϱ⠽¬¿öÁý´Ï´Ù. ȯÀÚ´Â ÀϹÝÀûÀ¸·Î ÀÌ·¯ÇÑ ±â±â¸¦ ´õ Æí¾ÈÇÏ°Ô ÀåÂøÇÒ ¼ö ÀÖÀ¸¸ç ºÎÇǰ¡ Å©Áö ¾Ê´Ù°í ´À³§´Ï´Ù. ÀÌ·¯ÇÑ Áøº¸´Â º¸´Ù Á¤È®ÇÑ Áø´Ü, ´õ ³ªÀº ȯÀÚ °ü¸®, º¸´Ù È¿°úÀûÀÎ °£Áú °ü¸®·Î À̾îÁý´Ï´Ù.

°£Áú ¸ð´ÏÅ͸µ ±â±âÀÇ ±â¼úÀû º¹À⼺

ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü´Â ÁýÁßÀûÀÎ ±³À°À̳ª Áö¼ÓÀûÀÎ ±â¼ú Áö¿øÀÌ ÇÊ¿äÇÑ ±â±â¿¡ µ·À» ¾²Áö ¾Ê±â ¶§¹®¿¡ ¸Å¿ì º¹ÀâÇÑ ¸ð´ÏÅ͸µ ±â±âÀÇ µµÀÔÀº Á¦¾àÀ» ¹ÞÀ» ¼ö ÀÖ½À´Ï´Ù. º¹ÀâÇÑ ±â±â¸¦ Á¶ÀÛÇÏ°í µ¥ÀÌÅ͸¦ ºÐ¼®Çϱâ À§ÇØ °Ç°­ °ü¸® Á÷¿øÀº Ưº°ÇÑ ±³À°ÀÌ ÇÊ¿äÇÏ¸ç ±³À°¿¡ ½Ã°£ÀÌ °É¸®°í Àη ºÎÁ·À» ÃÊ·¡ÇÕ´Ï´Ù. ¸ð´ÏÅ͸µ °á°úÀÇ Á¤È®¼º°ú ½Å·Ú¼ºÀº ±â¼úÀû º¹À⼺À¸·Î ÀÎÇØ ¹ß»ýÇϱ⠽¬¿î ÀÎÀ§Àû ½Ç¼ö·Î ÀÎÇØ À§Çè¿¡ óÇÒ ¼ö ÀÖÀ¸¸ç, ÀÇ·á ±â°üÀº º¹ÀâÇÑ ¸ð´ÏÅ͸µ ¼Ö·ç¼ÇÀÇ µµÀÔÀ» ¿¬±âÇϰųª ÇÇÇÒ ¼ö ÀÖ½À´Ï´Ù. °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù.

COVID-19ÀÇ ¿µÇâ

°£Áú ¸ð´ÏÅ͸µ ¹× Áø´ÜÀº À¯Çà¿¡ ÀÇÇØ Áß´ÜµÈ °Ç°­ °ü¸® ¼­ºñ½º Áß ÇϳªÀÔ´Ï´Ù. COVID-19 ȯÀÚÀÇ °ø°£À» È®º¸Çϱâ À§ÇØ Æ¯Á¤ Áø´Ü °Ë»ç¸¦ Æ÷ÇÔÇÑ ¼±ÅÃÀû Ä¡·á°¡ ¿¬±âµÇ°Å³ª ÁߴܵǾú½À´Ï´Ù. À̰ÍÀº °£ÁúÀÇ ¹ß°ß°ú Ä¡·á ¹æ¹ý¿¡µµ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. °Ç°­ °ü¸® ´ã´çÀÚ´Â ´ë¸é Áø·á¸¦ ÁÙÀ̱â À§ÇØ °¡»ó ÁøÂû°ú °°Àº ¿ø°Ý ÀÇ·á ¼­ºñ½º¸¦ ÀÌ¿ëÇϱ⠽ÃÀÛÇß½À´Ï´Ù. ¿ø°Ý ÀǷḦ ÅëÇØ °£Áú ȯÀÚ¸¦ ¿ø°ÝÀ¸·Î ¸ð´ÏÅ͸µÇϰí Ä¡·á Àü·«À» º¯°æÇÒ ¼ö ÀÖ½À´Ï´Ù. À¯Çà ±â°£ µ¿¾È °£Áú ȯÀÚ´Â Áø´Ü°ú Ä¡·á¸¦ ¹Þ´Â °ÍÀÌ Áö¿¬µÇ¾úÀ» ¼ö ÀÖ½À´Ï´Ù. °Ç°­ °ü¸® ¼­ºñ½º°¡ Á¤»óÀûÀ¸·Î ¾÷¹«¸¦ Àç°³Çϸé ȯÀÚÀÇ Ã¼·ù°¡ ¹ß»ýÇÏ°í °£Áú ¸ð´ÏÅ͸µÀÇ Çʿ伺ÀÌ ³ô¾ÆÁú ¼ö ÀÖ½À´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È ±âÁ¸ µð¹ÙÀ̽º ºÐ¾ß°¡ ÃÖ´ë°¡ µÉ Àü¸ÁÀÔ´Ï´Ù.

ÀüÅëÀûÀÎ ±â±â ºÎ¹®Àº È¿À²¼º°ú ¾ÈÀü¼ºÀ¸·Î ÀÎÇØ À¯¸®ÇÑ ¼ºÀåÀ» ´Þ¼ºÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ½ÃÀåÀº ±âÁ¸ ±â±â ºÎ¹®¿¡ ÀÇÇØ Áö¹èµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âÁ¸ ±â±â¡±´Â ³úÆÄ(EEG)¸¦ »ç¿ëÇÏ¿© ȯÀÚ¸¦ Áö¼ÓÀûÀ¸·Î ¸ð´ÏÅ͸µÇÏ´Â µ¥ »ç¿ëµÇ´Â ±â±â¸¦ ¸»ÇÕ´Ï´Ù. ±âÁ¸ ±â±â´Â º´¿ø ¹× Ŭ¸®´Ð¿¡¼­µµ ÀϹÝÀûÀ¸·Î Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µ¿¡ »ç¿ëµË´Ï´Ù. Àü¹®°¡´Â ¹ßÀÛÀÇ À¯ÇüÀ» Á¤È®ÇÏ°Ô Áø´ÜÇÏ°í ±âÁ¸ ±â¼úÀ» »ç¿ëÇÏ¿© ÃÖÀûÀÇ Ä¡·á Á¤Ã¥À» Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿ä¼Ò´Â Áö¼ÓÀûÀÌ°í ºñħ½ÀÀûÀÎ °£Áú ¸ð´ÏÅ͸µÀÇ Çʿ伺 Áõ°¡¿Í ¿¬°üµÉ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÃÖ÷´Ü ¾ÆÀÌÅÛÀÌ ½ÃÀå¿¡ ³ª¼­°í ÀÖ´Â °Íµµ ÀÌ ºÐ¾ßÀÇ È®´ë¸¦ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

½ÉºÎ³úÀڱؿä¹ý ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)ÀÌ ¿¹»óµË´Ï´Ù.

½ÉºÎ³úÀڱؿä¹ý(DBS)Àº ÁÖ·Î ÆÄŲ½¼º´À̳ª º»Å¼ºÁøÀüÀ» Æ÷ÇÔÇÑ ¿îµ¿Àå¾ÖÀÇ Ä¡·á¿¡ ä¿ëµÇ°í Àֱ⠶§¹®¿¡ ¿¹Ãø±â°£ Áß º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) ¼ºÀå·üÀº ½ÉºÎ³úÀڱؿä¹ý ºÐ¾ß°¡ °¡Àå ³ôÀ» °ÍÀ¸·Î ¿¹»ó ÇÕ´Ï´Ù. DBS´Â ¶ÇÇÑ °£Áú Ä¡·áÀÇ ´ë¾ÈÀ¸·Î¼­, ƯÈ÷ ´Ù¸¥ Ä¡·á¹ýÀÌ ´É¼÷ÇÏÁö ¾ÊÀº ¾à¹° ÀúÇ×¼º °£ÁúÀÇ »óȲ¿¡¼­ ¿¬±¸µÇ°í ÀÖ½À´Ï´Ù. DBS´Â ÀüÇüÀûÀÎ °£Áú ¸ð´ÏÅ͸µ ±â¼úÀÌ ¾Æ´ÏÁö¸¸ °£Áú Ä¡·áÀÇ Àüü À̹ÌÁö¿¡ ±â¿©ÇÕ´Ï´Ù. °£Áú Ä¡·á·Î DBS¸¦ °í·ÁÇϱâ Àü¿¡ öÀúÇÑ ¸ð´ÏÅ͸µ°ú Æò°¡°¡ ÇÊ¿äÇÕ´Ï´Ù. EEG(³úÆÄ) ¸ð´ÏÅ͸µ ¹× ºñµð¿À EEG ¸ð´ÏÅ͸µÀº °£Áú ¹ßÀÛ Áß È¯ÀÚÀÇ ³ú Ȱµ¿À» ĸóÇϰí Á¶»çÇÏ´Â µ¥ »ç¿ëµÇ´Â µÎ °¡Áö °£Áú ¸ð´ÏÅ͸µ µµ±¸ÀÔ´Ï´Ù.

ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇÏ´Â Áö¿ª

¿¹Ãø ±â°£ µ¿¾È ºÏ¹Ì°¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À̰ÍÀº ¹Ì±¹¿¡¼­ °£Áú ¸ð´ÏÅ͸µ ±â±â È®ÀåÀÇ ÁÖ¿ä ¿äÀÎÀº ½Å°æ Áúȯ, ƯÈ÷ °£ÁúÀÇ À¯º´·üÀÌ ³ô°í ÃÖÁ¾ »ç¿ëÀÚ°¡ ¸¹´Ù´Â °ÍÀÔ´Ï´Ù. ¶ÇÇÑ °£ÁúÀÇ À¯º´·ü Áõ°¡·Î ȯÀÚ¸¦ È¿°úÀûÀ¸·Î Ä¡·áÇϱâ À§ÇØ °£Áú ¸ð´ÏÅ͸µ ±â±âÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ ºÐ¾ß ½ÃÀåÀº ¾÷°èÀÇ ÁÖ¿ä ±â¾÷ÀÌ Á¸ÀçÇϰí Á¦Ç° °³¹ß°ú ¿¬±¸¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí Àֱ⠶§¹®¿¡ ±Þ¼ÓÈ÷ È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. µû¶ó¼­ Á¶»ç ´ë»óÀÌ µÈ ½ÃÀåÀº ¾Õ¼­ ¾ð±ÞÇÑ Ãø¸é¿¡¼­ ºÏ¹ÌÀ¸·Î È®´ëµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)ÀÌ °¡Àå ³ôÀº Áö¿ª:

°£ÁúÀ¯º´·ü »ó½Â, ½Å°æÁúȯ¿¡ ´ëÇÑ ÀǽÄÀÇ Çâ»ó, ÀÇ·á±â¼úÀÇ Çâ»óÀ¸·Î ¾Æ½Ã¾ÆÅÂÆò¾çÁö¿ªÀÇ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)ÀÌ ¿¹Ãø±â°£¿¡¼­ °¡Àå ³ô¾ÆÁú °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. °£Áú ¸ð´ÏÅ͸µ ±â±â¸¦ ÅëÇÑ Àå±â ºñµð¿À EEG ¸ð´ÏÅ͸µÀº ÀÇ·á ÇöÀå¿¡¼­ ¼öÇàµË´Ï´Ù. °Ô´Ù°¡ Áý¿¡¼­ »ç¿ëÇÒ ¼ö ÀÖ´Â ¸î °¡Áö °¡Á¬ÀÌ ¸¸µé¾îÁ³À¸¸ç, ȯÀÚ°¡ ÀÚ½ÅÀÇ °Ç°­À» ½±°Ô ÁöÄѺ¼ ¼ö ÀÖ½À´Ï´Ù. ¸ð´ÏÅ͸µ ±â±â´Â °£Áú°ú °ü·Ã Áúº´¿¡ ´ëÇÑ ÀǽÄÀÌ Áõ°¡ÇÏ°í °Ç°­ °ü¸® ½Ã½ºÅÛÀÇ ¹ß´ÞÀÇ °á°ú·Î »ç¿ëµË´Ï´Ù. ƯÈ÷ °Ç°­ °ü¸® ½Ã½ºÅÛÀÌ ±Þ¼ÓÈ÷ È®´ëµÇ°í ÀÖ´Â ±¹°¡¿¡¼­´Â ÀÌ·¯ÇÑ °æÇâÀÌ µÎµå·¯Á³½À´Ï´Ù.

¹«·á ¸ÂÃã¼³Á¤ ¼­ºñ½º

ÀÌ º¸°í¼­¸¦ ±¸µ¶ÇÏ´Â °í°´Àº ´ÙÀ½ ¹«·á ¸ÂÃã¼³Á¤ ¿É¼Ç Áß Çϳª¸¦ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Ãß°¡ ½ÃÀå ±â¾÷ÀÇ Á¾ÇÕÀû ÇÁ·ÎÆÄÀϸµ(3°³»ç±îÁö)
    • ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®(3°³»ç±îÁö)
  • Áö¿ª ¼¼ºÐÈ­
    • °í°´ÀÇ °ü½É¿¡ ÀÀÇÑ ÁÖ¿ä±¹ ½ÃÀå Ãß°è,¿¹Ãø ¹× º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)(ÁÖ: Ÿ´ç¼º È®Àο¡ µû¸§)
  • °æÀï º¥Ä¡¸¶Å·
    • Á¦Ç° Æ÷Æ®Æú¸®¿À, Áö¸®Àû Á¸Àç, Àü·«Àû Á¦ÈÞ¿¡ ±â¹ÝÇÑ ÁÖ¿ä ±â¾÷ º¥Ä¡¸¶Å·

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼­¹®

  • °³¿ä
  • ÀÌÇØ°ü°èÀÚ
  • Á¶»ç ¹üÀ§
  • Á¶»ç ¹æ¹ý
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • µ¥ÀÌÅÍ ºÐ¼®
    • µ¥ÀÌÅÍ °ËÁõ
    • Á¶»ç Á¢±Ù
  • Á¶»ç ¼Ò½º
    • 1Â÷ Á¶»ç ¼Ò½º
    • 2Â÷ Á¶»ç ¼Ò½º
    • ÀüÁ¦Á¶°Ç

Á¦3Àå ½ÃÀå µ¿Ç⠺м®

  • ¼Ò°³
  • ¼ºÀå ÃËÁø¿äÀÎ
  • ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • À§Çù
  • Á¦Ç°ºÐ¼®
  • ±â¼ú ºÐ¼®
  • ÃÖÁ¾ »ç¿ëÀÚ ºÐ¼®
  • ½ÅÈï ½ÃÀå
  • COVID-19ÀÇ ¿µÇâ

Á¦4Àå Porter's Five Forces ºÐ¼®

  • °ø±Þ±â¾÷ÀÇ Çù»ó·Â
  • ±¸¸ÅÀÚÀÇ Çù»ó·Â
  • ´ëüǰÀÇ À§Çù
  • ½Å±Ô Âü°¡¾÷üÀÇ À§Çù
  • °æÀï ±â¾÷°£ °æÀï °ü°è

Á¦5Àå ¼¼°è °£Áú ¸ð´ÏÅ͸µ ±â±â ½ÃÀå : Á¦Ç°º°

  • ¼Ò°³
  • Á¾·¡ÀÇ ±â±â
    • °¨½Ã µð¹ÙÀ̽º
      • ³úÆÄ(EEG) ±â±â
      • Ç¥ÁØ ³úÆÄ(EEG) ±â±â
      • ºñµð¿À ³úÆÄ(EEG) µð¹ÙÀ̽º
      • ÈÞ´ë¿ë ³úÆÄ°è
      • ±ÙÀüµµ °Ë»ç(EMG) ±â±â
      • Àڱ⠿£ÆÄ·Î±×·¡ÇÇ(MEG) ±â±â
      • ±âŸ °¨½Ã ±â±â
    • ³ú½ÉºÎ Àڱرâ±â
  • ¿þ¾î·¯ºí µð¹ÙÀ̽º

Á¦6Àå ¼¼°è °£Áú ¸ð´ÏÅ͸µ ±â±â ½ÃÀå : À¯Çüº°

  • ¼Ò°³
  • Àü½Å ¹ßÀÛ
  • ±¹¼Ò ¹ßÀÛ

Á¦7Àå ¼¼°è °£Áú ¸ð´ÏÅ͸µ ±â±â ½ÃÀå : ±â¼úº°

  • ¼Ò°³
  • ³ú½ÉºÎ ÀÚ±Ø
  • °¡¼Óµµ°è
  • ¹ÝÀÀ¼º ½Å°æ ÀÚ±Ø
  • ¹ÌÁÖ ½Å°æ ÀÚ±Ø
  • ±âŸ ±â¼ú

Á¦8Àå ¼¼°è °£Áú ¸ð´ÏÅ͸µ ±â±â ½ÃÀå : ȯÀÚ À¯Çüº°

  • ¼Ò°³
  • °í·ÉÀÚ¿ë
  • ¼ºÀÎ
  • ¼Ò¾Æ

Á¦9Àå ¼¼°è °£Áú ¸ð´ÏÅ͸µ ±â±â ½ÃÀå : À¯Åë ä³Îº°

  • ¼Ò°³
  • ¿Â¶óÀÎ ÆÇ¸Å
  • ¼Ò¸Å ¸ÅÃâ
  • Á÷Á¢ ÀÔÂû
  • ±âŸ À¯Åë ä³Î

Á¦10Àå ¼¼°è °£Áú ¸ð´ÏÅ͸µ ±â±â ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • ¼Ò°³
  • º´¿ø
  • ¿Ü·¡ ¼­ºñ½º
  • ½Å°æ¼¾ÅÍ
  • Áø´Ü¼¾ÅÍ
  • ±âŸ ÃÖÁ¾ »ç¿ëÀÚ

Á¦11Àå ¼¼°è °£Áú ¸ð´ÏÅ͸µ ±â±â ½ÃÀå :Áö¿ªº°

  • ¼Ò°³
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • ´ºÁú·£µå
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ³²¹Ì
    • ¾Æ¸£ÇîÆ¼³ª
    • ºê¶óÁú
    • Ä¥·¹
    • ±âŸ ³²¹Ì
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • īŸ¸£
    • ³²¾ÆÇÁ¸®Ä«
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦12Àå ÁÖ¿ä ¹ßÀü

  • °è¾à, ÆÄÆ®³Ê½Ê, Çù¾÷ ¹× ÇÕÀÛÅõÀÚ(JV)
  • Àμö ¹× ÇÕº´
  • ½ÅÁ¦Ç° ¹ß¸Å
  • »ç¾÷ È®´ë
  • ±âŸ ÁÖ¿ä Àü·«

Á¦13Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • Abbott Laboratories
  • Bioserenity
  • Boston Scientific Corporation
  • Brain Sentinel Inc.
  • Cadwell industries
  • Compumedics USA inc
  • Emfit Corporation
  • Empatica Inc
  • Epilert
  • General Electric company
  • Kninklijke Philips NV
  • Masimo
  • Medpage Ltd
  • Medtronic
  • Natus Medical Incorporated
  • Neurosoft
  • Neurowave systems
  • Nihon Kohden Corporation
  • Nonin
  • Pulse Guard International Ltd.
JHS 23.11.10

According to Stratistics MRC, the Global Epilepsy Monitoring Devices Market is accounted for $556.7 million in 2023 and is expected to reach $876.5 million by 2030 growing at a CAGR of 6.7% during the forecast period. Epilepsy is a neurological ailment marked by recurring seizures, and epilepsy monitoring devices are instruments and technology used in medicine to identify, track, and manage the condition. These tools are essential for the early detection and management of epilepsy, as well as for enhancing the quality of life for those who have the condition. With the help of this portable EEG gadget, patients may be monitored while going about their daily business. It aids in catching seizures that might not happen while you're in the hospital and it includes implanting electrodes into the brain to capture brain activity in people with drug-resistant epilepsy. When non-invasive EEG techniques don't yield enough details, it's employed.

According to the World Health Organization's February 2022 update, around 50 million people worldwide have epilepsy, making it one of the most common neurological diseases globally.

Market Dynamics:

Driver:

Growing prevalence of epilepsy

The need for epilepsy monitoring equipment grows along with the number of people who have the condition. To successfully manage their illness, a growing patient population needs additional diagnostic and monitoring instruments. Moreover, the need for therapy optimization results from a growing patient population. In order to ensure that the best therapies are employed and that the correct quantities of pharmaceuticals are provided, monitoring devices assist healthcare providers in customizing treatment regimens to each patient and combat the rising frequency of epilepsy, governmental organizations and medical institutions frequently develop public health campaigns. These initiatives can concentrate on enhancing accessibility to monitoring and diagnosing services thus propel the market growth.

Restraint:

Limited access due to high cost

Access to epilepsy monitoring equipment may be hampered by high expenses, especially for individuals without sufficient insurance or financial resources. This may result in inadequate or delayed diagnosis and care. Patients who are required to pay a substantial amount of the cost of monitoring equipment could experience financial difficulties. This can deter individuals from getting the essential diagnostic procedures or medical care. The expensive expense of monitoring equipment may completely prohibit their adoption in areas with little resources, such as poor nations, leaving people with epilepsy underserved thus hamper the market growth.

Opportunity:

Ability to change flow rates and reach high pressure

Real-time data analysis, additional monitoring channels, and enhanced signal processing are all features of digital EEG systems. More electrodes are used in high-density EEG systems to record brain activity. These devices offer more precise geographical data, which is useful for locating the source of seizures and more accurately describing epileptic activity. Monitoring has become less obtrusive and more user-friendly because to the miniaturization of monitoring equipment, such as wearable EEG headsets. Patients typically find these gadgets to be more comfortable and less bulky to wear. Together, these developments lead to more precise diagnoses, better patient care, and more effective management of epilepsy.

Threat:

Technical complexity of epilepsy monitoring devices

The adoption of very complicated monitoring devices can be constrained because healthcare providers might be reluctant to spend money on equipment that needs intensive training and continuing technical assistance. To operate and analyze data from complicated equipment, healthcare personnel require specific training and result in lengthy training times and a staffing scarcity. The accuracy and dependability of monitoring findings may be jeopardized by human mistakes, which are made more likely by technical complexity and healthcare institutions may postpone or avoid deploying complicated monitoring solutions.

COVID-19 Impact

Epilepsy monitoring and diagnosis were among the healthcare services that were disrupted by the epidemic. In order to make room for COVID-19 patients, elective procedures including certain diagnostic tests were postponed or cancelled. This had an effect on how epilepsy was identified and treated. Healthcare practitioners started using telehealth services, such as virtual consultations, to reduce in-person visits. Telehealth made it possible to remotely monitor epilepsy patients and modify treatment strategies; often negating the need for physical monitoring equipment. During the pandemic, patients with epilepsy may have had delays in seeking a diagnosis or treatment. Once healthcare services resume regular operations, this might result in a backlog of patients and increased need for epilepsy monitoring.

The conventional devices segment is expected to be the largest during the forecast period

The conventional devices segment is estimated to have a lucrative growth, due to its efficiency and safety, the market is projected to be dominated by the traditional devices segment. The term "conventional devices" refers to equipment used to continuously monitor patients using electroencephalograms (EEG). Conventional equipment is also commonly utilized in hospitals and clinics for on-going monitoring. Professionals can accurately diagnose the kind of seizure to provide the best course of therapy using conventional technology. These elements can be linked to the rising need for continuous, non-invasive epilepsy monitoring. The availability of such cutting-edge items on the market also aids in the segment's expansion.

The deep brain stimulation segment is expected to have the highest CAGR during the forecast period

The deep brain stimulation segment is anticipated to witness the highest CAGR growth during the forecast period, as deep brain stimulation (DBS) has been mainly employed to treat movement disorders including Parkinson's disease and essential tremor. It has also been investigated as a possible epileptic therapy option, particularly in situations of drug-resistant epilepsy where other therapies have failed. Although DBS is not a typical epilepsy monitoring technology, it does contribute to the overall picture of epilepsy therapy. A thorough monitoring and assessment are required before contemplating DBS as a therapy for epilepsy. EEG (electroencephalogram) and video-EEG monitoring are two types of epilepsy monitoring tools used to capture and examine a patient's brain activity during seizures.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to the main drivers of the expansion of epilepsy monitoring devices in the United States are the high prevalence of neurological illnesses, particularly epilepsy, and the sheer volume of end users. Moreover, due to the rising prevalence of epilepsy, there is an increased need for epilepsy monitoring equipment in order to treat patients effectively. Additionally, it is anticipated that the market in this area would expand faster due to the presence of the key industry players there and their heavy investment in product development and research. The studied market is therefore anticipated to increase in the North American area as a result of the aforementioned aspects.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, owing to the rising epilepsy prevalence, rising awareness of neurological diseases, and improvements in medical technology. Long-term video-EEG monitoring with epilepsy monitoring equipment has been done in medical settings. Additionally, several gadgets were made to be used at home, making it easier for patients to keep an eye on their health. Monitoring devices were used as a result of rising epilepsy and associated condition awareness as well as the development of the healthcare system. This was especially true in nations with healthcare systems that were expanding quickly.

Key players in the market

Some of the key players profiled in the Epilepsy Monitoring Devices Market include: Abbott Laboratories, Bioserenity, Boston Scientific Corporation, Brain Sentinel Inc., Cadwell industries, Compumedics USA inc, Emfit Corporation, Empatica Inc, Epilert, General Electric company, Kninklijke Philips N.V., Masimo, Medpage Ltd, Medtronic, Natus Medical Incorporated, Neurosoft, Neurowave systems, Nihon Kohden Corporation, Nonin and Pulse Guard International Ltd.

Key Developments:

In September 2023, Abbott announced that it has completed the acquisition of Bigfoot Biomedical, a leader in developing smart insulin management systems for people with diabetes.

In September 2023, Boston Scientific Corporation announced it has entered into a definitive agreement to acquire Relievant Medsystems, Inc., a privately held medical technology company that has developed and commercialized the Intracept® Intraosseous Nerve Ablation System to treat vertebrogenic pain, a form of chronic low back pain.

In August 2023, Cadwell Launches Sierra NMUS1 Ultrasound and Sierra 4 Software. The new Sierra NMUS1 offers high-resolution neuromuscular and musculoskeletal ultrasound, and needle guidance capabilities, with integrated controls.

Products Covered:

  • Conventional Devices
  • Wearable Devices

Types Covered:

  • Generalized Seizures
  • Focal Seizures

Technologies Covered:

  • Deep Brain Stimulation
  • Accelometry
  • Responsive Neurostimulation
  • Vagus Nerve Stimulation
  • Other Technologies

Patient Types Covered:

  • Geriatric
  • Adults
  • Paediatric

Distribution Channels Covered:

  • Online Sales
  • Retail Sales
  • Direct Tenders
  • Other Distribution Channels

End Users Covered:

  • Hospitals
  • Ambulatory Services
  • Neurology Centers
  • Diagnostic Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Epilepsy Monitoring Devices Market, By Product

  • 5.1 Introduction
  • 5.2 Conventional Devices
    • 5.2.1 Monitoring Devices
      • 5.2.1.1 Electroencephalogram (EEG) Devices
      • 5.2.1.1.1 Standard Electroencephalogram (EEG) Devices
      • 5.2.1.1.2 Video Electroencephalogram (EEG) Devices
      • 5.2.1.1.3 Other/Ambulatory EEG Devices
      • 5.2.1.2 Electromyography (EMG) Devices
      • 5.2.1.3 Magnetoencphalography (MEG) Devices
      • 5.2.1.4 Other Monitoring Devices
    • 5.2.2 Deep Brain Stimulation Devices
  • 5.3 Wearable Devices

6 Global Epilepsy Monitoring Devices Market, By Type

  • 6.1 Introduction
  • 6.2 Generalized Seizures
  • 6.3 Focal Seizures

7 Global Epilepsy Monitoring Devices Market, By Technology

  • 7.1 Introduction
  • 7.2 Deep Brain Stimulation
  • 7.3 Accelometry
  • 7.4 Responsive Neurostimulation
  • 7.5 Vagus Nerve Stimulation
  • 7.6 Other Technologies

8 Global Epilepsy Monitoring Devices Market, By Patient Type

  • 8.1 Introduction
  • 8.2 Geriatric
  • 8.3 Adults
  • 8.4 Paediatric

9 Global Epilepsy Monitoring Devices Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Online Sales
  • 9.3 Retail Sales
  • 9.4 Direct Tenders
  • 9.5 Other Distribution Channels

10 Global Epilepsy Monitoring Devices Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals
  • 10.3 Ambulatory Services
  • 10.4 Neurology Centers
  • 10.5 Diagnostic Centers
  • 10.6 Other End Users

11 Global Epilepsy Monitoring Devices Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Abbott Laboratories
  • 13.2 Bioserenity
  • 13.3 Boston Scientific Corporation
  • 13.4 Brain Sentinel Inc.
  • 13.5 Cadwell industries
  • 13.6 Compumedics USA inc
  • 13.7 Emfit Corporation
  • 13.8 Empatica Inc
  • 13.9 Epilert
  • 13.10 General Electric company
  • 13.11 Kninklijke Philips N.V.
  • 13.12 Masimo
  • 13.13 Medpage Ltd
  • 13.14 Medtronic
  • 13.15 Natus Medical Incorporated
  • 13.16 Neurosoft
  • 13.17 Neurowave systems
  • 13.18 Nihon Kohden Corporation
  • 13.19 Nonin
  • 13.20 Pulse Guard International Ltd.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦